États-Unis · Plateformes & données · Finviz

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Publié par Finviz · États-Unis il y a 9 h

Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a…

Lire l'article complet sur Finviz Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (elite.finviz.com)

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

À lire aussi

Clorox forecasts 3.5%-4.5% organic sales growth as input cost inflation rises to $240M

JAKKS Pacific: 3 Key Takeaways for Long-Term Investors

Here’s why Palantir’s stock is down despite a ‘bombastic’ quarter

Disney eyes thousands of layoffs, asks managers to target 20% savings, Bloomberg News reports

Stock market after midterm elections: What S&P 500 history shows

Locksley Resources Options Expire Without Exercise

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Partager

À lire aussi

Clorox forecasts 3.5%-4.5% organic sales growth as input cost inflation rises to $240M

JAKKS Pacific: 3 Key Takeaways for Long-Term Investors

Here’s why Palantir’s stock is down despite a ‘bombastic’ quarter

Disney eyes thousands of layoffs, asks managers to target 20% savings, Bloomberg News reports

Stock market after midterm elections: What S&P 500 history shows

Locksley Resources Options Expire Without Exercise